{
  "abstract": "The UK’s surveillance system is limited by data that are fragmented, difficult and slow to access, and of variable quality, write Anthony Harnden and Alison Cave",
  "authors": [
    {
      "affiliations": [
        "Medicines and Healthcare products Regulatory Agency"
      ],
      "name": "Alison Cave"
    },
    {
      "affiliations": [
        "Medicines and Healthcare products Regulatory Agency"
      ],
      "name": "Anthony Harnden"
    }
  ],
  "title": "Proactive drug safety surveillance should be at the heart of the new Health Data Research Service",
  "uid": "efd981e8-4b6b-5745-b3f3-ebe9229a0efb"
}